VISIT US IN CHICAGO JUNE 2-4 AT BOOTH 2073!

Dr. Kris Discusses Methotrexate in ALL

Mark G. Kris, MD
Published: Tuesday, Jun 14, 2011

Mark G. Kris, MD from Memorial Sloan-Kettering Cancer Center discusses Methotrexate in Acute Lymphocytic Leukemia (ALL).

Dr. Kris says that by using a regimen that included high dose methotrexate with leucovorin rescue, the cure rate was improved to over 80%. Using this, which Dr. Kris says has now become a standard of care, more than 80% of children with Acute Lymphocytic Leukemia are cured and that the boost in the cure rate was only by changing how methotrexate is given.
Mark G. Kris, MD from Memorial Sloan-Kettering Cancer Center discusses Methotrexate in Acute Lymphocytic Leukemia (ALL).

Dr. Kris says that by using a regimen that included high dose methotrexate with leucovorin rescue, the cure rate was improved to over 80%. Using this, which Dr. Kris says has now become a standard of care, more than 80% of children with Acute Lymphocytic Leukemia are cured and that the boost in the cure rate was only by changing how methotrexate is given.

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Oncology Briefings™: Emerging Treatment Options for Patients With High-Risk AMLMay 31, 20181.0
Oncology Briefings™: Updates in Pediatric Hepatic Veno-Occlusive Disease: Integrating Novel Therapeutic Strategies to Overcome Post-Transplant ObstaclesMay 31, 20181.0
Publication Bottom Border
Border Publication
x